ERROR 404

DUPIXENT is indicated in:

  • Asthma: as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • Atopic Dermatitis: for the treatment of adult and pediatric patients aged 6 months and older with moderate‑to‑severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
  • Chronic Obstructive Pulmonary Disease: as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with a history of exacerbations and guided by biomarkers of type 2 inflammation (eg, blood eosinophils).
  • Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): as an add‑on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
  • Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
  • Prurigo Nodularis: for the treatment of adult patients with prurigo nodularis (PN).